Intracept Basivertebral Nerve Ablation in St. Louis

Most low back pain gets attributed to a disc, a facet joint, or a nerve root. There is a fourth generator that is routinely missed: the vertebral endplate — the thin layer of bone between the disc and the vertebral body itself.

When an endplate is damaged and inflamed, it produces a deep, persistent, midline ache that behaves unlike disc or facet pain. It is often worse with sitting and with bending forward, and it tends not to respond to the treatments aimed at the structures around it. This is vertebrogenic pain, and it has its own name because it has its own mechanism.

The endplate is supplied by the basivertebral nerve, which runs inside the vertebral body itself. The Intracept procedure reaches that nerve through the bone and interrupts it with radiofrequency energy. Nothing is implanted, nothing is fused, and no disc or joint is touched.

This is one of the few pain generators with a visible imaging signature, and that changes the diagnostic approach.

Damaged, inflamed endplates produce characteristic MRI findings known as Modic changes, graded as Type 1 or Type 2. Their presence at the affected levels is what identifies a patient as having vertebrogenic pain rather than pain from a neighboring structure. Every major trial of this procedure required Type 1 or Type 2 Modic changes as an entry criterion, and selection is the reason those trials produced the results they did.

Diagnosis therefore combines the clinical pattern — deep midline pain, worse sitting and flexing, persistent beyond six months — with an MRI read specifically for endplate signal change rather than for disc herniation alone. If your existing MRI was reported without reference to Modic changes, that does not mean they are absent; it means the study was read for a different question.

The evidence here is unusually strong for an interventional pain procedure, and it is worth being precise about what was shown.

A prospective randomized controlled trial across 20 US sites enrolled 140 patients with chronic low back pain of at least six months and Modic Type 1 or 2 changes between L3 and S1, randomized to basivertebral nerve ablation or continued standard care. At the prespecified interim analysis the treatment arm showed superiority on every primary and secondary outcome, and an independent data management committee recommended halting enrollment and offering the control group early crossover.

At three months, Oswestry Disability Index scores improved by 25.3 points in the ablation arm against 4.4 points with standard care — an adjusted difference of 20.9 points. Pain scores improved by 3.46 against 1.02. A clinically meaningful improvement of at least 10 ODI points was reached by 74.5 percent of the ablation group against 32.7 percent of the standard care group.

Follow-up of the treatment arm at 24 months found those gains held: mean disability improved 28.5 points from a baseline of 44.5, roughly 72 percent of patients reported at least half their pain gone, and 31 percent were pain-free at two years. No serious device-related or procedure-related adverse events were reported through 24 months.

At enrollment, 36 percent of patients in that trial were actively taking opioids. At 24 months after ablation, 62 percent fewer patients were taking them.

That is the outcome this practice cares about most. The aim of interventional pain care is not to add a procedure to a medication regimen — it is to treat the generator directly so the medication becomes unnecessary. A procedure that measurably reduces opioid burden two years later is doing the thing the practice exists to do.

The randomized trial described above compared ablation against standard care and was open label — patients knew which arm they were in. That matters in procedural research, where the placebo response is substantial. A separate earlier trial did use a sham control, and its treatment arm maintained improvement at two years, but the strongest and largest comparison is against continued standard care rather than against a convincing sham.

Industry involvement is also present in this literature, including in the published cost-effectiveness analysis. The randomized results are multicenter and peer-reviewed, but you are entitled to know who funded the work when weighing it.

And the selection criteria are narrow by design. These outcomes come from patients with confirmed Modic Type 1 or 2 changes at specific levels who had already failed six months of conservative care. They say very little about someone whose endplates look normal, and nothing at all about back pain in general. As with every procedure here, the honest position is that patient selection is doing most of the work.

Intracept is an outpatient procedure performed under local anesthetic with live X-ray guidance. A small channel is created through the pedicle into the vertebral body, the basivertebral nerve is treated with radiofrequency energy, and the instruments are withdrawn. Nothing is left behind.

No sedation is used. You are awake and responsive throughout, and most patients drive themselves home — the same protocol as radiofrequency ablation elsewhere in the spine.

There are no activity restrictions afterward. Most patients resume normal activity, including work, within two to four hours. That is unusual among procedures that involve entering bone, and it follows from the fact that nothing is implanted and no structure is destabilized.

Relief is not immediate. Because the procedure interrupts a nerve rather than removing a mechanical compression, improvement typically develops over the weeks following treatment rather than on the day.

There is no national Medicare coverage determination for basivertebral nerve ablation. Several Medicare contractors publish their own local coverage determinations for it, each with specific criteria, and commercial policies vary. Coverage is therefore checked against your particular plan rather than assumed.

The criteria that recur across published policies mirror the trial entry requirements, and they align with good practice regardless of who is paying: chronic low back pain persisting six months or more, documented failure of conservative care, and Modic Type 1 or 2 endplate changes on MRI at the levels to be treated.

We do not publish prices. Call (314) 481-5000 and the office will check your specific coverage and tell you where you stand before anything is scheduled. Note that an authorization, if one is obtained, is not itself a guarantee of payment — plans reserve review of the claim after it is submitted.

Intracept is not a first step and it is not a last resort. It is the treatment for one specific generator, chosen once that generator has been identified.

Conservative care comes first. Where pain persists, the diagnostic question is which structure is responsible — and the answer determines the treatment. Facet radiofrequency ablation treats the facet joints, epidural steroid injection treats an irritated nerve root, SI joint fusion treats the sacroiliac joint, and MILD [Minimally Invasive Lumbar Decompression] treats stenosis from a thickened ligamentum flavum. Intracept treats the endplate. They are not alternatives to one another; they are answers to different questions.

Because nothing is implanted or fused, Intracept preserves every later option. Dr. Gurpreet Singh Padda, MD, MBA, MHP is a licensed physician and surgeon with surgical privileges, and the practice leads with the least invasive option that can answer the question.

For a fuller discussion of the endplate as a pain source, see our article on basivertebral nerve ablation and vertebrogenic back pain.